(NP (NP (NP (NN Glucocorticoid) (NNS receptors)) (PP (IN in) (NP (JJ normal) (NNS leukocytes))) (: :)) (NP (NP (NNS effects)) (PP (IN of) (NP-COOD (NP (NN age)) (, ,) (NP (NN gender)) (, ,) (NP (NN season)) (, ,) (CC and) (NP (NN plasma) (NN cortisol) (NNS concentrations)))) (. .)))
(S (NP-SBJ (PRP We)) (VP (VBD measured) (NP (NP (NP (NN glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NP (JJ mononuclear) (NNS leukocytes)) (PRN (-LRB- -LRB-) (NP (NN MNL)) (-RRB- -RRB-))) (VP (VBN isolated) (NP (-NONE- *)) (PP (IN from) (NP (NP (JJ peripheral) (NN blood)) (PP (IN of) (NP (NP (CD 145) (ADJP (RB apparently) (JJ healthy)) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD 86) (NNS men)) (CC and) (NP (CD 59) (NNS women))) (-RRB- -RRB-))))))))))) (. .))
(S (S (NP-SBJ-7 (NP (DT An) (JJ age-related) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN GR)))))) (VP (VBD was) (VP (VBN suggested) (NP (-NONE- *-7)) (PP (IN between) (NP-COOD (NP (NP (NNS subjects)) (ADJP (ADJP (JJR younger)) (PP (IN than) (NP (CD 20) (NNS years))))) (CC and) (NP (JJ elderly) (NNS subjects)))))) (: ;)) (S (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT no) (JJ apparent) (JJ seasonal) (NN variation)) (PP (IN in) (NP (NN GR))))) (. .)))
(S (NP-SBJ (NP (NN Gender) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN GR)))))) (VP (VBD was) (RB not) (ADJP-PRD (JJ significant)) (, ,) (SBAR (IN although) (S (NP-SBJ (NNS women)) (VP (VBD showed) (NP (ADJP (RB slightly) (JJR fewer)) (NN GR)))))) (. .))
(S (NP-SBJ-8 (NP (CD Eight) (NNS patients)) (PP (IN with) (NP (NN (polymyositis dermatomyositis))))) (VP (VBD were) (VP (VBN examined) (NP (-NONE- *-8)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ-9 (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN GR)) (PP (IN in) (NP (NN MNL)))))) (VP (MD could) (VP (VB be) (VP (VBN down-regulated) (NP (-NONE- *-9)) (PP (IN by) (NP-LGS (PRP$ their) (JJ cognate) (NNS ligands))))))))))))) (. .))
(S (NP-SBJ-10 (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NN GR)) (PP (IN in) (NP (NP (NN MNL)) (PP (IN from) (NP (DT these) (NNS patients)))))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (NP (-NONE- *-10)) (PP-TMP (NP (CD one) (NN month)) (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN prednisolone) (NN therapy))))))) (. .))
(S (ADVP (RB However)) (, ,) (PP (IN in) (NP (JJ normal) (NNS subjects))) (, ,) (NP-SBJ (NP (DT the) (NN GR)) (PP (IN in) (NP (NN MNL)))) (VP (VBD did) (RB not) (VP (VB demonstrate) (NP (JJ circadian) (NN variation)) (, ,) (PP (IN in) (NN contrast) (TO to) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NN plasma) (NN cortisol))))))) (. .))
